Patient Rating:

4.8 out of 5

36 Patient Ratings
27 Patient Comments

Craig H. Selzman, M.D.

Clinical Details

Schedule An Appointment Clinical Office Address
(801) 587-9348 University Hospital
Cardiovascular Center
50 N Medical Dr
Salt Lake City, UT 84132
Map

Bio

Dr. Craig Selzman is an Associate Professor of Surgery in the Division of Cardiothoracic Surgery at the University of Utah who specializes in the care of patients requiring heart surgery. He earned his undergraduate degree at Amherst College and medical degree at Baylor College of Medicine. He received his General and Cardiothoracic Surgery training at the University of Colorado and is Board-Certified in both fields. Dr. Selzman was on faculty at the University of North Carolna before joining the faculty at University of Utah in 2008.

Dr. Selzman is the Surgical Director of the Cardiac Mechanical Support and Heart Transplant program as well as Surgical Director of the Lung and Heart/Lung Transplant program. In addition to his role in the advanced Heart Failure and Artifiical Heart program, he specializes in complex valvular heart disease including reoperative heart surgery, adult congenital heart disease, and aortic root reconstruction. He is one of a few surgeons in the Intermountain West with significant experience with minimally invasive heart surgery for a wide variety of disease, and, in particular, mitral valve repair.

Dr. Selzman is heavily involved with clinical research related to advanced heart failure, transplantation, and ventricular assist devices. He also has an active basic science collaboration with many of our researchers here at the University of Utah. Dr. Selzman is one of a handful of cardiothoracic surgeons that runs a laboratory funded by the National Institute of Health. His research focus is related to examining mechanisms of heart recovery.

Board Certification and Academic Information

Academic Departments Surgery - Associate Professor
Academic Divisions Cardiothoracic Surgery
Board Certification American Board of Surgery (General Surgery)
American Board of Thoracic Surgery (Thoracic Surg)

Patient Ratings

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Likelihood of recommending care provider
5.0
My confidence in care provider
4.9
Time care provider spent with me
4.8
Care provider spoke using clear language
4.8
Care provider's effort to include me in decisions
4.8
Care provider's concern for questions & worries
4.8
Care provider's explanation of condition/problem
4.8
Wait time at clinic
4.2
Care provider's friendliness and courtesy
4.9

Patient Comments

Patient comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

July 24, 2014

All good

July 20, 2014

Excellent care

May 13, 2014

Above and beyond.

May 09, 2014

I've already recommended Dr. Selzman to at least 6 people.

May 09, 2014

Dr. Selzman is a man of great integrity, honesty and one who embodies trust during the most vulnerable and difficult times of life. I have known him now since 2010 when he performed my 3rd open heart surgical procedure, and the most complicated. He brought me back to life and became my friend for life. He had also been my advocate during complex medical complications with right sided heart failure and subsequent renal issues. Most there don't understand the life-altering and frightening complications of this situation, but he does and he has been an advocate for specialized treatment and a chance at life. He is always such a pleasure to see and he makes me laugh and gives me hope. He is my friend and I am grateful to him and also to his incredible nurse, Heather Clark, RN. She is so deeply compassionate, kind and amazing at follow-up. Thank you.

March 03, 2014

I have always trusted in Dr. Selzman. If I didnt, I wouldn't fly from Oregon for my surgeries and care from him. He is the best Nationally as far as I am concerned. I would recommend him and I do.

February 09, 2014

Dr. Selzman understood the 29 days of hospitalization I had experienced and showed concern for how I was dealing with that. He also quickly assured me that I was now doing fine.

January 17, 2014

Perhaps the best experience I've had with any physician and other care providers in my 66 years.

January 15, 2014

The team was terrific.

January 10, 2014

my physical response to this corrective surgery has been difficult. Having Dr Selzman and his team provide excellence with attentive and compassionate care made all the difference. Thank you!

January 10, 2014

The care we received here is better than any care we've received elsewhere!

December 06, 2013

great

November 21, 2013

Dr.Salizman is wonderful

September 23, 2013

the doctor felt my medical wasn't severe enough to operate. I'm just scared that something more is going to happen with my luck to. I want to know I haven't been forgotten about.

July 15, 2013

We are totally impressed with everyone involved in my surgery, recovery and follow up. Everyone were exceptional professionals.

May 28, 2013

all good

May 13, 2013

Left with no questions. When they did arrise it was convenient to get answers

May 09, 2013

Good experience Staff were very helpful.

April 29, 2013

I was treated like. person. with concern and care. I am asked if I understand my condition and explained what I don't. I am explained what is happening to me. I am reassured that I am in good hands. and I feel at ease because I am being talked to and looked at.

February 18, 2013

Very pleased with the degree of knowledge and concern

January 07, 2013

Terri was very informative during my pre-op visit, great personality and concern. I would highly recommend anyone visiting your practice for sugical intervention to be followed by Dr. Allen. In my opinion, he is the best rounded professional on staff in his position. My family concurs that he was very informative, caring, and aware of my situation whenever he rounded on me. He has a great demeanor and followed through efficiently. I felt that any/all of my concerns were addressed and confident that he would relay them to Dr. Selzman. I didn't get the same quality of care with Dr. Kim.

August 07, 2012

Dr. Salzman is the best

June 25, 2012

The UUH LVAD team is tops in my book!!!

June 24, 2012

Outstanding care and concerns

June 11, 2012

This was a very positive and comforting visit.

April 25, 2012

very good.

February 22, 2012

Good experience as bad health situations go!

Academic Profile

Board Certification and Academic Information

Academic Departments Surgery - Associate Professor
Academic Divisions Cardiothoracic Surgery
Board Certification American Board of Surgery (General Surgery)
American Board of Thoracic Surgery (Thoracic Surg)

Academic Office Locations

Academic Office Phone Number Academic Office Address
(801) 587-9348 School of Medicine
Division of Cardiothoracic Surgery
30 N Medical Dr
Salt Lake City, UT 84132

Academic Bio

As an Associate Professor of Cardiothoracic Surgery in the School of Medicine at the University of Utah, Dr. Selzman is heavily invested in the future of our next generation of physicians and surgeons. He is actively involved with medical student teaching, general surgical education, and training of young cardiac surgeons. He has been involved with educational strategies at the national level through his professional societies. Dr. Selzman has mentored dozens of trainees- both in the clinical and basic sciences - over the last 15 years, many which currently hold faculty positions in academic medical centers.

In addition to his involvement with clinical research (see Clinical Trials), Dr. Selzman has an active, NIH-funded basic science laboratory. He collaborates with many of the investigators within the Molecular Medicine Program and with the Integrated Advanced Heart Failure Program. He has published over 100 manuscripts in peer-reviewed journals as well as authored several textbook chapters. His laboratory is focused on transcriptional regulation and mechanisms of myocardial recovery. His team uses several models for investigation ranging from individual cardiomyocytes to transgenic mice as well as larger translational studies in sheep, goats, and humans.

In addition to his clinical and research responsibilites here at the University of Utah, Dr. Selzman carries many national and international positions including NIH study sections, Thoracic Transplantation committees, and professional organizational responsibilites.

Education

Education History

Type School Degree
Residency University of Colorado at Denver and Health Sciences Center
Cardiothoracic Surgery
Resident
Residency University of Colorado at Denver and Health Sciences Center
Surgery
Resident
Internship University of Colorado at Denver and Health Sciences Center
Surgery
Intern
Professional Medical Baylor College of Medicine
Medicine
M.D.
Undergraduate Amherst College
Political Science
B.A.

Publications

Selected Provider Publications

Journal Article

  1. Ventricular Assist Devices or Inotropic Agents in Status 1A Patients? Survival Analysis of the United Network of Organ Sharing Database.Wozniak CJ, Stehlik J, Baird BC, McKellar SH, Song HK, Drakos SG, Selzman CH (2014). Ventricular Assist Devices or Inotropic Agents in Status 1A Patients? Survival Analysis of the United Network of Organ Sharing Database. Ann Thorac Surg, 97(4), 1364-72.
  2. Morbidity and mortality in heart transplant candidates supported with mechanical circulatory support: is reappraisal of the current United network for organ sharing thoracic organ allocation policy justified?Wever-Pinzon O, Drakos SG, Kfoury AG, Nativi JN, Gilbert EM, Everitt M, Alharethi R, Brunisholz K, Bader FM, Li DY, Selzman CH, Stehlik J (2013). Morbidity and mortality in heart transplant candidates supported with mechanical circulatory support: is reappraisal of the current United network for organ sharing thoracic organ allocation policy justified? Circulation, 127(4), 452-62.
  3. In vitro pulsatility analysis of axial-flow and centrifugal-flow left ventricular assist devices.Stanfield JR, Selzman CH (2013). In vitro pulsatility analysis of axial-flow and centrifugal-flow left ventricular assist devices. J Biomech Eng, 135(3), 34505.
  4. Surgical Treatment for Ischemic Heart Failure (STICH) Trial: Mode of Death Results.LID - 10.1016/j.jchf.2013.04.012 [doi]Carson P, Wertheimer J, Miller A, OConnor CM, Pina IL, Selzman C, Sueta C, She L, Greene D, Lee KL, Jones RH, Velazquez EJ (2013). Surgical Treatment for Ischemic Heart Failure (STICH) Trial: Mode of Death Results.LID - 10.1016/j.jchf.2013.04.012 [doi]. JACC Heart Fail, 1(5).
  5. A longitudinal study of the course of asymptomatic antibody-mediated rejection in heart transplantation.Kfoury AG, Snow GL, Budge D, Alharethi RA, Stehlik J, Everitt MD, Miller DV, Drakos SG, Reid BB, Revelo MP, Gilbert EM, Selzman CH, Bader FM, Connelly JJ, Hammond ME (2012). A longitudinal study of the course of asymptomatic antibody-mediated rejection in heart transplantation. J Heart Lung Transplant, 31(1), 46-51.
  6. Improved survival in heart transplant patients living at high altitude.Wozniak CJ, Baird BC, Stehlik J, Drakos SG, Bull DA, Patel AN, Selzman CH (2012). Improved survival in heart transplant patients living at high altitude. J Thorac Cardiovasc Surg, 143(3), 735-741.e1.
  7. Inhibitory kappa-B kinase-beta inhibition prevents adaptive left ventricular hypertrophy.Andersen NM, Tang R, Li L, Javan H, Zhang XQ, Selzman CH (2012). Inhibitory kappa-B kinase-beta inhibition prevents adaptive left ventricular hypertrophy. J Surg Res, 178(1), 105-9.
  8. Recovery from decompensated heart failure is associated with a distinct, phase-dependent gene expression profile.Andersen NM, Stansfield WE, Tang RH, Rojas M, Patterson C, Selzman CH (2012). Recovery from decompensated heart failure is associated with a distinct, phase-dependent gene expression profile. J Surg Res, 178(1), 72-80.
  9. Bridge to recovery: understanding the disconnect between clinical and biological outcomes.Drakos SG, Kfoury AG, Stehlik J, Selzman CH, Reid BB, Terrovitis JV, Nanas JN, Li DY (2012). Bridge to recovery: understanding the disconnect between clinical and biological outcomes. Circulation, 126(2), 230-41.
  10. Flow characteristics of continuous-flow left ventricular assist devices in a novel open-loop system.Stanfield JR, Selzman CH, Pardyjak ER, Bamberg S (2012). Flow characteristics of continuous-flow left ventricular assist devices in a novel open-loop system. ASAIO J, 58(6), 590-6.
  11. Impact of Ventricular Assist Device Complications on Posttransplant Survival: An Analysis of the United Network of Organ Sharing Database.LID - S0003-4975(12)02482-4 [pii]LID - 10.1016/j.athoracsur.2012.10.080 [doi]Healy AH, Baird BC, Drakos SG, Stehlik J, Selzman CH (2012). Impact of Ventricular Assist Device Complications on Posttransplant Survival: An Analysis of the United Network of Organ Sharing Database.LID - S0003-4975(12)02482-4 [pii]LID - 10.1016/j.athoracsur.2012.10.080 [doi]. Ann Thorac Surg.
  12. Selzman CH, Desjardins G, Patel AN, Davis E, Dick S, Stehlik J (2012). Complications associated with the use of left ventricular assist device therapy in an adult patient with Ebstein's anomaly. Ann Thorac Surg, 93(1), 297-9.
  13. Antibody testing for cardiac antibody-mediated rejection: which panel correlates best with cardiovascular death?Revelo MP, Stehlik J, Miller D, Snow GL, Everitt MD, Budge D, Bader FM, Alharethi RA, Gilbert EM, Reid BB, Selzman CH, Hammond ME, Kfoury AG (2011). Antibody testing for cardiac antibody-mediated rejection: which panel correlates best with cardiovascular death? J Heart Lung Transplant, 30(2), 144-50.
  14. Left ventricular assist device unloading effects on myocardial structure and function: current status of the field and call for action.Drakos SG, Kfoury AG, Selzman CH, Verma DR, Nanas JN, Li DY, Stehlik J (2011). Left ventricular assist device unloading effects on myocardial structure and function: current status of the field and call for action. Curr Opin Cardiol, 26(3), 245-55.
  15. Changing outcomes in patients bridged to heart transplantation with continuous- versus pulsatile-flow ventricular assist devices: an analysis of the registry of the International Society for Heart and Lung Transplantation.Nativi JN, Drakos SG, Kucheryavaya AY, Edwards LB, Selzman CH, Taylor DO, Hertz MI, Kfoury AG, Stehlik J (2011). Changing outcomes in patients bridged to heart transplantation with continuous- versus pulsatile-flow ventricular assist devices: an analysis of the registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant, 30(8), 854-61.
  16. Impact of donor left ventricular hypertrophy on survival after heart transplant.Wever Pinzon O, Stoddard G, Drakos SG, Gilbert EM, Nativi JN, Budge D, Bader F, Alharethi R, Reid B, Selzman CH, Everitt MD, Kfoury AG, Stehlik J (2011). Impact of donor left ventricular hypertrophy on survival after heart transplant. Am J Transplant, 11(12), 2755-61.
  17. Allograft rejection in patients supported with continuous-flow left ventricular assist devices.Healy AH, Mason NO, Hammond ME, Reid BB, Clayson SE, Drakos SG, Kfoury AG, Patel AN, Bull DA, Budge D, Alharethi RA, Bader FM, Gilbert EM, Stehlik J, Selzman CH (2011). Allograft rejection in patients supported with continuous-flow left ventricular assist devices. Ann Thorac Surg, 92(5), 1601-7; discussion 1607.
  18. Effects of the 2006 U.S. thoracic organ allocation change: analysis of local impact on organ procurement and heart transplantation.Nativi JN, Kfoury AG, Myrick C, Peters M, Renlund D, Gilbert EM, Bader F, Singhal AK, Everitt M, Fisher P, Bull DA, Selzman C, Stehlik J (2010). Effects of the 2006 U.S. thoracic organ allocation change: analysis of local impact on organ procurement and heart transplantation. J Heart Lung Transplant, 29(3), 235-9.
  19. Obesity and left ventricular assist device driveline exit site infection.Raymond AL, Kfoury AG, Bishop CJ, Davis ES, Goebel KM, Stoker S, Selzman CH, Clayson SE, Smith H, Cowley CG, Alharethi R, Budge D, Reid BB (2010). Obesity and left ventricular assist device driveline exit site infection. ASAIO J, 56(1), 57-60.
  20. The impact of bridge-to-transplant ventricular assist device support on survival after cardiac transplantation.Bull DA, Reid BB, Selzman CH, Mesley R, Drakos S, Clayson S, Stoddard G, Gilbert E, Stehlik J, Bader F, Kfoury A, Budge D, Eckels DD, Fuller A, Renlund D, Patel AN (2010). The impact of bridge-to-transplant ventricular assist device support on survival after cardiac transplantation. J Thorac Cardiovasc Surg, 140(1), 169-73.
  21. Invited commentary.Selzman C (2010). Invited commentary. Ann Thorac Surg, 90(1), 123.
  22. Impact of mechanical unloading on microvasculature and associated central remodeling features of the failing human heart.Drakos SG, Kfoury AG, Hammond EH, Reid BB, Revelo MP, Rasmusson BY, Whitehead KJ, Salama ME, Selzman CH, Stehlik J, Clayson SE, Bristow MR, Renlund DG, Li DY (2010). Impact of mechanical unloading on microvasculature and associated central remodeling features of the failing human heart. J Am Coll Cardiol, 56(5), 382-91.
  23. Regression of pressure-induced left ventricular hypertrophy is characterized by a distinct gene expression profile.Stansfield WE, Charles PC, Tang RH, Rojas M, Bhati R, Moss NC, Patterson C, Selzman CH (2009). Regression of pressure-induced left ventricular hypertrophy is characterized by a distinct gene expression profile. J Thorac Cardiovasc Surg, 137(1), 232-8, 238e1-8.
  24. Muscle ring finger 1 mediates cardiac atrophy in vivo.Willis MS, Rojas M, Li L, Selzman CH, Tang RH, Stansfield WE, Rodriguez JE, Glass DJ, Patterson C (2009). Muscle ring finger 1 mediates cardiac atrophy in vivo. Am J Physiol Heart Circ Physiol, 296(4), H997-H1006.
  25. Prior human leukocyte antigen-allosensitization and left ventricular assist device type affect degree of post-implantation human leukocyte antigen-allosensitization.Drakos SG, Kfoury AG, Kotter JR, Reid BB, Clayson SE, Selzman CH, Stehlik J, Fisher PW, Merida M 3rd, Eckels DD, Brunisholz K, Horne BD, Stoker S, Li DY, Renlund DG (2009). Prior human leukocyte antigen-allosensitization and left ventricular assist device type affect degree of post-implantation human leukocyte antigen-allosensitization. J Heart Lung Transplant, 28(8), 838-42.
  26. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice.Callis TE, Pandya K, Seok HY, Tang RH, Tatsuguchi M, Huang ZP, Chen JF, Deng Z, Gunn B, Shumate J, Willis MS, Selzman CH, Wang DZ (2009). MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest, 119(9), 2772-86.
  27. Contributions of extravascular and intravascular cells to fibrin network formation, structure, and stability.Campbell RA, Overmyer KA, Selzman CH, Sheridan BC, Wolberg AS (2009). Contributions of extravascular and intravascular cells to fibrin network formation, structure, and stability. Blood, 114(23), 4886-96.
  28. Periostin is a novel factor in cardiac remodeling after experimental and clinical unloading of the failing heart.Stansfield WE, Andersen NM, Tang RH, Selzman CH (2009). Periostin is a novel factor in cardiac remodeling after experimental and clinical unloading of the failing heart. Ann Thorac Surg, 88(6), 1916-21.
  29. Jones RH, Velazquez EJ, Michler RE, Sopko G, Oh JK, OConnor CM, Hill JA, Menicanti L, Sadowski Z, Desvigne-Nickens P, Rouleau JL, Lee KL, STICH Hypothesis 2 Investigators (2009). Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med, 360(17), 1705-17.
  30. Kouretas PC, Kaza AK, Burch PT, Witte MK, Clayson SE, Everitt MD, Selzman CH (2009). Experience with the Levitronix CentriMag in the pediatric population as a bridge to decision and recovery. Artif Organs, 33(11), 1002-4.
  31. Proteasome inhibition promotes regression of left ventricular hypertrophy.Stansfield WE, Tang RH, Moss NC, Baldwin AS, Willis MS, Selzman CH (2008). Proteasome inhibition promotes regression of left ventricular hypertrophy. Am J Physiol Heart Circ Physiol, 294(2), H645-50.
  32. Invited commentary on: Gene Transfer of Endothelial Nitric Oxide Synthase Attenuates Flow-induced Pulmonary Hypertension in RabbitsSelzman CH (2008). Invited commentary on: Gene Transfer of Endothelial Nitric Oxide Synthase Attenuates Flow-induced Pulmonary Hypertension in Rabbits. Ann Thorac Surg, 85(2), 585-6.
  33. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure.Chen JF, Murchison EP, Tang R, Callis TE, Tatsuguchi M, Deng Z, Rojas M, Hammond SM, Schneider MD, Selzman CH, Meissner G, Patterson C, Hannon GJ, Wang DZ (2008). Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci U S A, 105(6), 2111-6.
  34. Myocardin inhibits cellular proliferation by inhibiting NF-kappaB(p65)-dependent cell cycle progression.Tang RH, Zheng XL, Callis TE, Stansfield WE, He J, Baldwin AS, Wang DZ, Selzman CH (2008). Myocardin inhibits cellular proliferation by inhibiting NF-kappaB(p65)-dependent cell cycle progression. Proc Natl Acad Sci U S A, 105(9), 3362-7.
  35. Inhibitory kappa B kinase-beta is a target for specific nuclear factor kappa B-mediated delayed cardioprotection.Moss NC, Tang RH, Willis M, Stansfield WE, Baldwin AS, Selzman CH (2008). Inhibitory kappa B kinase-beta is a target for specific nuclear factor kappa B-mediated delayed cardioprotection. J Thorac Cardiovasc Surg, 136(5), 1274-9.
  36. Characterization of a model to independently study regression of ventricular hypertrophy.Stansfield WE, Rojas M, Corn D, Willis M, Patterson C, Smyth SS, Selzman CH (2007). Characterization of a model to independently study regression of ventricular hypertrophy. J Surg Res, 142(2), 387-93.
  37. Proteasome inhibition attenuates infarct size and preserves cardiac function in a murine model of myocardial ischemia-reperfusion injury.Stansfield WE, Moss NC, Willis MS, Tang R, Selzman CH (2007). Proteasome inhibition attenuates infarct size and preserves cardiac function in a murine model of myocardial ischemia-reperfusion injury. Ann Thorac Surg, 84(1), 120-5.
  38. Off-pump insertion of continuous flow left ventricular assist devices.Selzman CH, Sheridan BC (2007). Off-pump insertion of continuous flow left ventricular assist devices. J Card Surg, 22(4), 320-2.
  39. IKKbeta inhibition attenuates myocardial injury and dysfunction following acute ischemia-reperfusion injury.Moss NC, Stansfield WE, Willis MS, Tang RH, Selzman CH (2007). IKKbeta inhibition attenuates myocardial injury and dysfunction following acute ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol, 293(4), H2248-53.
  40. Warshauer DM, Archer RK, Selzman CH, Tmaddon HS, Mauro MA (2007). Aortic pseudoaneurysm from penetrating superior vena cava stent. Radiology, 234(3), 901-4.
  41. Selzman CH, Chang PP, Vernon-Platt T, Bowen A, Kowalczyk S, Sherican BC (2007). Use of the Jarvik 2000 continous flow left ventricular assist device for acute myocardial infarction and cardiogenic shock. J Heart Lung Transplant, 26(7), 756-8.
  42. Thrombin generation in vascular tissue.Pathak A, Zhao R, Monroe DM, Roberts HR, Sheridan BC, Selzman CH, Stouffer GA (2006). Thrombin generation in vascular tissue. J Thromb Haemost, 4(1), 60-7.
  43. Gray NA Jr, Selzman CH (2006). Current status of the total artificial heart. Am Heart J, 152(1), 4-10.
  44. Heart transplantation for progressive cardiomyopathy as a manifestation of MELAS syndrome.Bhati RS, Sheridan BC, Mill MR, Selzman CH (2005). Heart transplantation for progressive cardiomyopathy as a manifestation of MELAS syndrome. J Heart Lung Transplant, 24(12), 2286-9.
  45. Interleukin-10 attenuates the response to vascular injury.Zimmerman MA, Reznikov LL, Raeburn CD, Selzman CH (2004). Interleukin-10 attenuates the response to vascular injury. J Surg Res, 121(2), 206-13.
  46. Relative contribution of the TNF-alpha receptors to murine intimal hyperplasia.Zimmerman MA, Reznikov LL, Sorensen AC, Selzman CH (2003). Relative contribution of the TNF-alpha receptors to murine intimal hyperplasia. Am J Physiol Regul Integr Comp Physiol, 284(5), R1213-8.
  47. Atherogenic effects of Chlamydia pneumoniae: refuting the innocent bystander hypothesis.Selzman CH, Netea MG, Zimmerman MA, Weinberg A, Reznikov LL, Grover FL, Dinarello CA (2003). Atherogenic effects of Chlamydia pneumoniae: refuting the innocent bystander hypothesis. J Thorac Cardiovasc Surg, 126(3), 688-93.
  48. Inhibition of intimal hyperplasia using the selective estrogen receptor modulator raloxifene.Selzman CH, Turner AS, Gaynor JS, Miller SA, Monnet E, Harken AH (2002). Inhibition of intimal hyperplasia using the selective estrogen receptor modulator raloxifene. Arch Surg, 137(3), 333-6.
  49. Interleukin-11 attenuates human vascular smooth muscle cell proliferation.Zimmerman MA, Selzman CH, Reznikov LL, Raeburn CD, Barsness K, McIntyre RC Jr, Hamiel CR, Harken AH (2002). Interleukin-11 attenuates human vascular smooth muscle cell proliferation. Am J Physiol Heart Circ Physiol, 283(1), H175-80.
  50. Lack of TNF-alpha attenuates intimal hyperplasia after mouse carotid artery injury.Zimmerman MA, Selzman CH, Reznikov LL, Miller SA, Raeburn CD, Emmick J, Meng X, Harken AH (2002). Lack of TNF-alpha attenuates intimal hyperplasia after mouse carotid artery injury. Am J Physiol Regul Integr Comp Physiol, 283(2), R505-12.
  51. Monocyte chemotactic protein-1 directly induces human vascular smooth muscle proliferation.Selzman CH, Miller SA, Zimmerman MA, Gamboni-Robertson F, Harken AH, Banerjee A (2002). Monocyte chemotactic protein-1 directly induces human vascular smooth muscle proliferation. Am J Physiol Heart Circ Physiol, 283(4), H1455-61.
  52. Functional reconstitution and regulation of IL-18 activity by the IL-18R beta chain.Kim SH, Reznikov LL, Stuyt RJ, Selzman CH, Fantuzzi G, Hoshino T, Young HA, Dinarello CA (2001). Functional reconstitution and regulation of IL-18 activity by the IL-18R beta chain. J Immunol, 166(1), 148-54.
  53. Suppression of tumor necrosis factor alpha production by cAMP in human monocytes: dissociation with mRNA level and independent of interleukin-10.Shames BD, McIntyre RC Jr, Bensard DD, Pulido EJ, Selzman CH, Reznikov LL, Harken AH, Meng X (2001). Suppression of tumor necrosis factor alpha production by cAMP in human monocytes: dissociation with mRNA level and independent of interleukin-10. J Surg Res, 99(2), 187-93.
  54. Interleukin-1beta deficiency results in reduced NF-kappaB levels in pregnant mice.Reznikov LL, Shames BD, Barton HA, Selzman CH, Fantuzzi G, Kim SH, Johnson SM, Dinarello CA (2000). Interleukin-1beta deficiency results in reduced NF-kappaB levels in pregnant mice. Am J Physiol Regul Integr Comp Physiol, 278(1), R263-70.
  55. Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells.Netea MG, Selzman CH, Kullberg BJ, Galama JM, Weinberg A, Stalenhoef AF, Van der Meer JW, Dinarello CA (2000). Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells. Eur J Immunol, 30(2), 541-9.
  56. Chlamydia pneumoniae activates nuclear factor kappaB and activator protein 1 in human vascular smooth muscle and induces cellular proliferation.Miller SA, Selzman CH, Shames BD, Barton HA, Johnson SM, Harken AH (2000). Chlamydia pneumoniae activates nuclear factor kappaB and activator protein 1 in human vascular smooth muscle and induces cellular proliferation. J Surg Res, 90(1), 76-81.
  57. The effect of raloxifene on coronary arteries in aged ovariectomized ewes.Gaynor JS, Monnet E, Selzman C, Parker D, Kaufman L, Bryant HU, Mallinckrodt C, Wrigley R, Whitehill T, Turner AS (2000). The effect of raloxifene on coronary arteries in aged ovariectomized ewes. J Vet Pharmacol Ther, 23(3), 175-9.
  58. Shames BD, Zallen GS, McIntryre RC Jr, Bensard DD, Pulido EJ, Miller SA, Pomerantz BJ, Selzman CH, Meng X, Harken AH (2000). Chemokines as mediators of diseases related to surgical conditions. Shock, 14(1), 1-7.
  59. Raeburn CD, Cleveland JC, Selzman CH, Harken AH (2000). Ischemic preconditioning in myocardial revascularization with intermittent aortic cross-clamping. J Card Surg, 15, 339-340.
  60. Gaynor JS, Monnet E, Selzman C, Parker D, Kaufman L, Bryant HU, Mallinckrodt C, Wrigley R, Whitehill T, Turner AS (2000). The effect of raloxifene on coronary arteries in aged ovariectomized ewes. Journal of Veterinary Pharmacology and Therapeutics, 23, 175-179.
  61. Utilization of endoscopic inoculation in a mouse model of intrauterine infection-induced preterm birth: role of interleukin 1beta.Reznikov LL, Fantuzzi G, Selzman CH, Shames BD, Barton HA, Bell H, McGregor JA, Dinarello CA (1999). Utilization of endoscopic inoculation in a mouse model of intrauterine infection-induced preterm birth: role of interleukin 1beta. Biol Reprod, 60(5), 1231-8.
  62. LPS-Induced NF-kappaB activation and TNF-alpha release in human monocytes are protein tyrosine kinase dependent and protein kinase C independent.Shames BD, Selzman CH, Pulido EJ, Meng X, Meldrum DR, McIntyre RC Jr, Harken AH, Banerjee A (1999). LPS-Induced NF-kappaB activation and TNF-alpha release in human monocytes are protein tyrosine kinase dependent and protein kinase C independent. J Surg Res, 83(1), 69-74.
  63. Liposomal delivery of purified inhibitory-kappaBalpha inhibits tumor necrosis factor-alpha-induced human vascular smooth muscle proliferation.Selzman CH, Shames BD, Reznikov LL, Miller SA, Meng X, Barton HA, Werman A, Harken AH, Dinarello CA, Banerjee A (1999). Liposomal delivery of purified inhibitory-kappaBalpha inhibits tumor necrosis factor-alpha-induced human vascular smooth muscle proliferation. Circ Res, 84(8), 867-75.
  64. The NFkappaB inhibitory peptide, IkappaBalpha, prevents human vascular smooth muscle proliferation.Selzman CH, Shames BD, McIntyre RC Jr, Banerjee A, Harken AH (1999). The NFkappaB inhibitory peptide, IkappaBalpha, prevents human vascular smooth muscle proliferation. Ann Thorac Surg, 67(5), 1227-31; discussion 1231-2.
  65. Inhibition of PARS attenuates endotoxin-induced dysfunction of pulmonary vasorelaxation.Pulido EJ, Shames BD, Selzman CH, Barton HA, Banerjee A, Bensard DD, McIntyre RC Jr (1999). Inhibition of PARS attenuates endotoxin-induced dysfunction of pulmonary vasorelaxation. Am J Physiol, 277(4 Pt 1), L769-76.
  66. Exogenous calcium preconditions myocardium from patients taking oral sulfonylurea agents.Cain BS, Meldrum DR, Meng X, Pulido EJ, Shames BD, Selzman CH, Banerjee A, Harken AH (1999). Exogenous calcium preconditions myocardium from patients taking oral sulfonylurea agents. J Surg Res, 86(2), 171-6.
  67. Interleukin-11 attenuates pulmonary inflammation and vasomotor dysfunction in endotoxin-induced lung injury.Sheridan BC, Dinarello CA, Meldrum DR, Fullerton DA, Selzman CH, McIntyre RC Jr (1999). Interleukin-11 attenuates pulmonary inflammation and vasomotor dysfunction in endotoxin-induced lung injury. Am J Physiol, 277(5 Pt 1), L861-7.
  68. Zimmerman MA, Selzman CH, Harken AH (1999). Surgical implications of therapeutic angiogenesis. Surgery, 125(3), 243-9.
  69. Interleukin-10 inhibits human vascular smooth muscle proliferation.Selzman CH, McIntyre RC Jr, Shames BD, Whitehill TA, Banerjee A, Harken AH (1998). Interleukin-10 inhibits human vascular smooth muscle proliferation. J Mol Cell Cardiol, 30(4), 889-96.
  70. Contemporary management of isolated iliac aneurysms.Krupski WC, Selzman CH, Floridia R, Strecker PK, Nehler MR, Whitehill TA (1998). Contemporary management of isolated iliac aneurysms. J Vasc Surg, 28(1), 1-11; discussion 11-3.
  71. TNF-alpha and myocardial depression in endotoxemic rats: temporal discordance of an obligatory relationship.Meng X, Ao L, Meldrum DR, Cain BS, Shames BD, Selzman CH, Banerjee A, Harken AH (1998). TNF-alpha and myocardial depression in endotoxemic rats: temporal discordance of an obligatory relationship. Am J Physiol, 275(2 Pt 2), R502-8.
  72. Class II cytokine receptor ligands inhibit human vascular smooth muscle proliferation.Selzman CH, Shames BD, Whitehill TA, Harken AH, McIntyre RC Jr (1998). Class II cytokine receptor ligands inhibit human vascular smooth muscle proliferation. Surgery, 124(2), 318-26; discussion 326-7.
  73. Increased levels of myocardial IkappaB-alpha protein promote tolerance to endotoxin.Shames BD, Meldrum DR, Selzman CH, Pulido EJ, Cain BS, Banerjee A, Harken AH, Meng X (1998). Increased levels of myocardial IkappaB-alpha protein promote tolerance to endotoxin. Am J Physiol, 275(3 Pt 2), H1084-91.
  74. Ovarian ablation alone promotes aortic intimal hyperplasia and accumulation of fibroblast growth factor.Selzman CH, Gaynor JS, Turner AS, Johnson SM, Horwitz LD, Whitehill TA, Harken AH (1998). Ovarian ablation alone promotes aortic intimal hyperplasia and accumulation of fibroblast growth factor. Circulation, 98(19), 2049-54.
  75. Interleukin-10 stabilizes inhibitory kappaB-alpha in human monocytes.Shames BD, Selzman CH, Meldrum DR, Pulido EJ, Barton HA, Meng X, Harken AH, McIntyre RC Jr (1998). Interleukin-10 stabilizes inhibitory kappaB-alpha in human monocytes. Shock, 10(6), 389-94.
  76. Interleukin-10 inhibits postinjury tumor necrosis factor-mediated human vascular smooth muscle proliferation.Selzman CH, Meldrum DR, Cain BS, Meng X, Shames BD, Ao L, Harken AH (1998). Interleukin-10 inhibits postinjury tumor necrosis factor-mediated human vascular smooth muscle proliferation. J Surg Res, 80(2), 352-6.
  77. Estrogen replacement inhibits intimal hyperplasia and the accumulation and effects of transforming growth factor beta1.Selzman CH, Gaynor JS, Turner AS, Whitehill TA, Horwitz LD, Harken AH (1998). Estrogen replacement inhibits intimal hyperplasia and the accumulation and effects of transforming growth factor beta1. J Surg Res, 80(2), 380-5.
  78. Shames BD, Selzman CH, Meng X, Meldrum DR, Cain BS, Harken AH (1998). Genes don't count. Arch Surg, 133(6), 667-9.
  79. Selzman CH, Shames BD, Miller SA, Pulido EJ, Meng X, McIntyre RC Jr, Harken AH (1998). Therapeutic implications of interleukin-10 in surgical disease. Shock, 10(5), 309-18.
  80. Alpha-adrenergic activation of myocardial NF kappa B during hemorrhage.Meldrum DR, Cleveland JC Jr, Sheridan BC, Rowland RT, Selzman CH, Banerjee A, Harken AH (1997). Alpha-adrenergic activation of myocardial NF kappa B during hemorrhage. J Surg Res, 69(2), 268-76.
  81. Chronic estrogen replacement inhibits aortic intimal hyperplasia independent of serum lipids.Selzman CH, Turner AS, Johnson SM, Cain BS, Harken AH, Whitehill TA (1997). Chronic estrogen replacement inhibits aortic intimal hyperplasia independent of serum lipids. J Card Surg, 12(4), 228-34.

Book Chapter

  1. Stansfield WE, Selzman CH (In Press, 2014). Mechanical Circulatory Support. In Taggart DP, Mohr FW (Ed.), Current concepts in cardiac surgery. Bentham Books.

Editorial

  1. Selzman CH (2012). Invited commentary on "Should patients age 60 and older be bridged to transplant using a contiuous flow left ventricular assist device". Ann Thorac Surg, 94(6), 2024.
  2. Selzman CH (2011). Invited commentary on "Aortic valve cyclic stretch causes increased remodeling activitiy and enhanced serotonin receptor responsiveness". Ann Thorac Surg, 92, 153-54.
  3. Selzman CH (2009). Invited commentary on "In-hospital outcomes of off-pump multi-vessel total arterial and conventional artery bypass grafting: single surgeon, single center experience". 88, 53.
  4. Selzman CH (2009). Invited commentary on "Role of tumor necrosis factor receptor 1 in sex differences of stem cell mediated cardioprotection". Ann Thorac Surg, 87, 819.
  5. Selzman CH (2008). Invited commentary on "Gene Transfer of endothelial nitric oxide synthase attenuates flow-induced pulmonary hypertension in rabbits. Ann Thorac Surg, 85, 585-6.
  6. NFkappaB decoys to prevent vein graft stenosis Invited Editorial on "inhibitory effects of NFkappaB decoy oligodeoxynucleotides on neointimal hyperplasia in a rabbit vein graft model"Selzman CH (2006). NFkappaB decoys to prevent vein graft stenosis Invited Editorial on "inhibitory effects of NFkappaB decoy oligodeoxynucleotides on neointimal hyperplasia in a rabbit vein graft model". J Mol Cell Cardiol, 41(3), 410-2.
  7. Selzman CH (2006). Invited commentary on "Improved mechanical reliability of the Heartmate XVE left ventricular assist device. Ann Thorac Surg, 82(4), 1418-1419.

Clinical Trials

Clinical Trials

Video & News